Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Ocular Therapeutix Inc’s stock clocked out at $7.53, down -0.53% from its previous closing price of $7.57. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 2.01 million shares were traded. OCUL stock price reached its highest trading level at $7.825 during the session, while it also had its lowest trading level at $7.27.
Ratios:
To gain a deeper understanding of OCUL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.59 and its Current Ratio is at 10.66. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.
On March 11, 2025, Needham started tracking the stock assigning a Buy rating and target price of $15.Needham initiated its Buy rating on March 11, 2025, with a $15 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 24 ’25 when Dugel Pravin sold 21,475 shares for $6.87 per share. The transaction valued at 147,533 led to the insider holds 3,520,318 shares of the business.
Heier Jeffrey S. sold 3,061 shares of OCUL for $21,029 on Feb 24 ’25. The Chief Scientific Officer now owns 265,998 shares after completing the transaction at $6.87 per share. On Feb 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,009 shares for $6.87 each. As a result, the insider received 20,672 and left with 210,078 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1197435648 and an Enterprise Value of 881118528. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.79 while its Price-to-Book (P/B) ratio in mrq is 3.77. Its current Enterprise Value per Revenue stands at 13.827 whereas that against EBITDA is -5.195.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.50, which has changed by -0.006596327 over the last 52 weeks, in comparison to a change of 0.07455289 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $4.06. The 50-Day Moving Average of the stock is 3.23%, while the 200-Day Moving Average is calculated to be -11.14%.
Shares Statistics:
It appears that OCUL traded 1.43M shares on average per day over the past three months and 2037240 shares per day over the past ten days. A total of 157.75M shares are outstanding, with a floating share count of 133.91M. Insiders hold about 15.79% of the company’s shares, while institutions hold 72.56% stake in the company. Shares short for OCUL as of 1743379200 were 12586674 with a Short Ratio of 8.83, compared to 1740700800 on 12048382. Therefore, it implies a Short% of Shares Outstanding of 12586674 and a Short% of Float of 7.95.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
